作者
Chinyu G Su, Xiaoming Wen, Shannon T Bailey, Wen Jiang, Shamina M Rangwala, Sue A Keilbaugh, Anne Flanigan, Sreekant Murthy, Mitchell A Lazar, Gary D Wu
发表日期
1999/8/15
期刊
The Journal of clinical investigation
卷号
104
期号
4
页码范围
383-389
出版商
American Society for Clinical Investigation
简介
Peroxisome proliferator-activated receptor γ (PPAR-γ), a member of the nuclear hormone receptor superfamily originally shown to play a critical role in adipocyte differentiation and glucose homeostasis, has recently been implicated as a regulator of cellular proliferation and inflammatory responses. Colonic epithelial cells, which express high levels of PPAR-γ protein, have the ability to produce inflammatory cytokines that may play a role in inflammatory bowel disease (IBD). We report here that PPAR-γ ligands dramatically attenuate cytokine gene expression in colon cancer cell lines by inhibiting the activation of nuclear factor-κB via an IκB-α–dependent mechanism. Moreover, thiazolidinedione ligands for PPAR-γ markedly reduce colonic inflammation in a mouse model of IBD. These results suggest that colonic PPAR-γ may be a therapeutic target in humans suffering from IBD.
J. Clin. Invest.104:383-389(1999).
引用总数
学术搜索中的文章
A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
CG Su, X Wen, ST Bailey, W Jiang, SM Rangwala… - The Journal of clinical investigation, 1999